Concerns about the COVID-19 shots have increased after a report that drug maker Moderna failed to inform the U.S. government ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

More than 1,500 people who have sought support from the vaccine damage payment scheme after being injured or bereaved as a ...

including an extensive pipeline of therapeutics in clinical trials that could be the booster shot the stock needs to generate a rebound. It's been more than four years since Moderna rose to ...

including an extensive pipeline of therapeutics in clinical trials that could be the booster shot the stock needs to generate a rebound. Let's discuss the pros and cons of buying Moderna stock.

Jared Holz, Mizuho Healthcare Sector strategist, joins 'Closing Bell Overtime' to talk Moderna and Novo Nordisk.

Ward said it would be good to see data from studies of other variant vaccine boosters to compare to the Moderna combination. Expert advisors "must already be thinking about the population at risk ...

The FDA has authorised booster shots with Moderna and Johnson & Johnson’s COVID-19 vaccines, a month after giving the go-ahead to a third-dose of Pfizer/BioNTech’s shot. It has also authorised ...